{"name":"Asahi Kasei Pharma Corporation","slug":"asahi-kasei-pharma-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"AK106-001616","genericName":"AK106-001616","slug":"ak106-001616","indication":"Other","status":"phase_2"},{"name":"AK159","genericName":"AK159","slug":"ak159","indication":"Other","status":"phase_1"},{"name":"AK1820","genericName":"AK1820","slug":"ak1820","indication":"Other","status":"phase_3"},{"name":"HC-58","genericName":"HC-58","slug":"hc-58","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Cyclophosphamide (CTX)","genericName":"Cyclophosphamide (CTX)","slug":"cyclophosphamide-ctx","indication":"Lymphomas (Hodgkin and non-Hodgkin)","status":"phase_3"},{"name":"AK156","genericName":"AK156","slug":"ak156","indication":"Non-small cell lung cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Mizoribine (MZR)","genericName":"Mizoribine (MZR)","slug":"mizoribine-mzr","indication":"Prevention of organ transplant rejection","status":"phase_3"}]}],"pipeline":[{"name":"Cyclophosphamide (CTX)","genericName":"Cyclophosphamide (CTX)","slug":"cyclophosphamide-ctx","phase":"phase_3","mechanism":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells.","indications":["Lymphomas (Hodgkin and non-Hodgkin)","Breast cancer","Ovarian cancer","Lung cancer","Severe systemic lupus erythematosus (SLE)"],"catalyst":""},{"name":"AK106-001616","genericName":"AK106-001616","slug":"ak106-001616","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK156","genericName":"AK156","slug":"ak156","phase":"phase_3","mechanism":"AK156 is a humanized monoclonal antibody that blocks the PD-1 checkpoint pathway to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"AK159","genericName":"AK159","slug":"ak159","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK1820","genericName":"AK1820","slug":"ak1820","phase":"phase_3","mechanism":"AK1820 is an investigational therapeutic targeting immune or inflammatory pathways, though its precise mechanism remains proprietary.","indications":[],"catalyst":""},{"name":"HC-58","genericName":"HC-58","slug":"hc-58","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mizoribine (MZR)","genericName":"Mizoribine (MZR)","slug":"mizoribine-mzr","phase":"phase_3","mechanism":"Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation.","indications":["Prevention of organ transplant rejection","Autoimmune and inflammatory diseases"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUEVmMzdtZEpkdzN0TzNDZFVnVVdESkNEUDNiN2tDdV9JeVQxejR4WWZLUVNOblQwMU43cnVMT0FPVEMzTkhnQXJ1VGhaclZ0QnptX2E5azdjNkdEMFRMMHNPWTRtb3g2ZEVYaFdFakFKSldPVURnaG5kT0Q3QTlZeFprV2xiLVZZRlFVakQ2NHhpQmFrZE9fTGZqbjhHRVJPQjRydGtGdzhodXU3MXRaWmdLQzY5bzNFbXUtUw?oc=5","date":"2026-02-26","type":"pipeline","source":"PharmTech.com","summary":"Impacts of Asahi Kasei’s Acquisition of Aicuris on Specialty Pharmaceutical Manufacturing - PharmTech.com","headline":"Impacts of Asahi Kasei’s Acquisition of Aicuris on Specialty Pharmaceutical Manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPYlhJZVp2bThSWnhHVllDYmtQd2FqQ1JrYmZpdVBYamxFcXdpeFhXeG5TTXBxRC1xN1FNVDk1dVUwemdZQnRJREdHS0picnhpQ1YzN25uXzFpbGVWZVp4OTg2ZG9SWnplUTRHWTMyVm9KVEZZTTJCZ1kyOEQzRG1wUjFlYzk2UXZ2ekRRb2I0TGJWX3ZRalBmdWhQcEQ3SFZRR2g3OUJOT2ZELXczS2dGVXRPU0FSWkRUQmtGTkdhQTdBZ3NIYlViYUpqTG5zRVR6R2dJYWd5TjRMcHM?oc=5","date":"2026-02-26","type":"pipeline","source":"Business Wire","summary":"Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris - Business Wire","headline":"Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNWTlXcTlURFpLNV85V2gzcTZ1NzlPaGV0dXV3OVMtTEZpUFlRTFhVWTJ5ZHJhZUpkYzI5dWhGeG1MWWJxMTlxTlR2UWNJVllMMF9JY2RrNjVVb1dTdkRCSHVzeWtqNUJ1WlpXajRJZlFvT0haM0R5WGJhbExUQzV0Y2UwVGJwa3VHdC1zNWRiSnNDX052bURWR1BUcm1BSVFRTlk5TjR2UG5lbzduemFsYm1GZFUzTV9WX0xRbHU2SmtqZ2tVTThIVmFyTkNqODZlMDg5WUVhZjdLVDRaVzhIUE9yb0VfbHpxVnl6SlhFWC0xcmlha25pcDRQQTRXU3VzaVh1bm05aVdoT1E3cjJDdnF3bFhFRV81V3pJcTFUZEw?oc=5","date":"2026-02-25","type":"deal","source":"Business Wire","summary":"Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds - Business Wire","headline":"Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for No","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPeDgtaDN3ZHd2alNqUTJSVmh6TGdOVzBwY09YbGxoOWV5QVlIbzVwMXRsRkVCX2s5aHdvY2hQR3k5eG9YbGVmTm5wS0QzMENTSkExNkIwcmtwcjREMXhtLWEwWjktOUJhNmpaeXlSNFJscktRbjIyUVhBVHREdXVzVllQU3ZtYkxLLWVjSVEycEpTWXhkTVkzTHhZcWhkLTRxS2FHVVVwUHRCZkl1TGhXNUpBSUVNZw?oc=5","date":"2026-02-25","type":"deal","source":"Investing.com UK","summary":"Asahi Kasei Pharma secures license for autoimmune compounds By Investing.com - Investing.com UK","headline":"Asahi Kasei Pharma secures license for autoimmune compounds By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOM1RvOUd5R3Bub1oxdkd5MGxvUmloQTh5aEsxY0ZfUDNJOUtoOXZ2aXk2ZlJ6Mzc1cTJ6dXByLUhQdHBPOHliUm03ZzdFclZJSkpxMENwNzB6ZkZXbW5LQXRfSnZJc2R1dW1kZ2ZwN0psb2hRVnJ1MW9JVVFHRWdxNC1fTXlRNWtiQXl5SGR6MmM?oc=5","date":"2026-02-19","type":"pipeline","source":"Yahoo Finance","summary":"MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients - Yahoo Finance","headline":"MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPSjR3bERoLXhQR2hYc2tRVzdJeGlaTjctNG9WMmZRamM4cmVRNDNUUDY5YUlOVHlEQmN2cnNyV2FTRGhmTWgwcnlaOVd0SVVFa2VKVEtteFM3bm5xUllYajB6d3Q5MnpzeGRkdk13UldPUGIxM0JscXM1UV9BN1hVRmlNVFBscklPbk1EeV9EQ1lpTWRWZWhZTXJfak9ncm1RcnRpUw?oc=5","date":"2026-02-17","type":"deal","source":"BioWorld News","summary":"Asahi Kasei Pharma acquires rights to Alchemedicine compounds - BioWorld News","headline":"Asahi Kasei Pharma acquires rights to Alchemedicine compounds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOaWVkR2xyaXlDSUJFTE5tTmZoVXE3bXgyLV9wVVNGb3FaYVpMUFpzNHkzZDgwRlBXVEY3TElVR1oxbnBVRXREMU9jM3pGb3pjUWRTbXNSeHNEZmc0YndiQU9pdDU3RnUyRWNvenN5ZDFXbE94X1JxUHMwN1BDYkpLdkNub3o1Sm85UzY1Y3ZpQW9yX0RnaU05UVFMOEEtaGZsZGFvRGM2dkFZdnJkd01wR25JYzF5S1B1SmRrRmpzOUVSc1o1VkE?oc=5","date":"2026-02-17","type":"deal","source":"ALCHEMPro","summary":"Japan's Alchemedicine & Asahi Kasei sign $270 mn license deal - ALCHEMPro","headline":"Japan's Alchemedicine & Asahi Kasei sign $270 mn license deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBSZkNkQXBHQTlyNHZtRDZ2ZjJET3V4U0pCMTFLLVl2YWRwMzdHY2g2NmozYndDanNSYkJFNGtLZmhCck45OFVjRTZHb2lfOTdKLVAtR2lLd2h3R1V1cDFN?oc=5","date":"2025-12-22","type":"pipeline","source":"asahi-kasei.com","summary":"Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark - asahi-kasei.com","headline":"Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark - asahi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE43YWZmalNrYmNvemxkU2tUWnVfLUpLdDZ4dG1MMTB3djVVSERoWTJiR3FiYzVDZ0gzdVdTVW9aS0w1eERyWGc5YUZVSm5EdEhMTEN1T0plYVpBc3JlVzVqeWZWa0VHLWMw?oc=5","date":"2025-09-09","type":"trial","source":"Wiley Online Library","summary":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study - Wiley Online Library","headline":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA0NkF6b19LV0tyUGtYbmYteHhWX1V0Vzc5WHVGaUZpNEgxT1hQLUVvZzJzN3FmcS1rOTlmampHcm9iMEtfdk0tYjlERmo5bEwyWFVTQUktSTh5NXllRjBN?oc=5","date":"2025-08-27","type":"pipeline","source":"Nature","summary":"Single-cell transcriptomic analysis of blood and bronchoalveolar lavage fluid in progressive fibrosing interstitial lung diseases - Nature","headline":"Single-cell transcriptomic analysis of blood and bronchoalveolar lavage fluid in progressive fibrosing interstitial lung","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQdHBFTHRKbGV2aWFWUmJyNEpMR3FQRVlkSzdQdFp1bk5ONE43QXpQd0xZRHdsTjI1czhVTHRhQzJ4VUNfenZKZFVfY1g1dTZQbEF3RTM3aVhWLTQxUy1oQmNMRFl5cUdTdzF3N0NjTENnaF9raWZBYUhoMDAwRmcwd1pfUF9EcDB1bmJIZUhLM0Z4cnNMVjMtSW9WX1N1cll2UkRGYm51ZU1Bd3BJelFYRmNmaFFja2U0aFZTdkdDNmhIYmVaWDg5Nl9iNzBuSDliN0xxd0ZPQzFtOTBrNjB2SVFSVmVhb3E4LVFfOUY2aldSRGtlQVJCOVJ4b3JWODQzb1VZUXM1cTY?oc=5","date":"2025-07-03","type":"trial","source":"BioSpace","summary":"Asahi Kasei Pharma Starts Phase III Study of Promising CIPN Prevention Therapy, ART-123 (Recomodulin™), to Enhance Treatment Options Worldwide - BioSpace","headline":"Asahi Kasei Pharma Starts Phase III Study of Promising CIPN Prevention Therapy, ART-123 (Recomodulin™), to Enhance Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPNXNGWW1xNzU3SWJ2YS1DbUtXVEF0enpJeXg4Q2lLQlo4Mi1CODhVVURjZDFFYmNvUUlmUUFXbmIwSjNXYWlxNk1TSDFkQ3B0MW5vUWVIWVpKZHRqd1B0Tk5MS2tXcE9vdkJtRWpFcmpIdk5uZk9GQ3VCYmoyemRsQXdBU0ZJZ18xblFmVm1WUEZzRk81V2NpLW01YXVZYWdYRGVCUWZYSzZRdWNlTVYwX3FkSmUwelVucXJoeW4yLUNpRkU0WkE?oc=5","date":"2024-12-12","type":"deal","source":"BioPharma APAC","summary":"Asahi Kasei Pharma Expands Global Reach with Exclusive Anti-CX3CR1 Antibody License - BioPharma APAC","headline":"Asahi Kasei Pharma Expands Global Reach with Exclusive Anti-CX3CR1 Antibody License","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":4,"phase_2":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}